pembrolizumab,nivolumab
merck,bms
['key,note,716', 'melanoma', 'keynote 716']
tox looks similar to keynote 716. the key question remains: is adjuvant therapy for stage 2 melanoma worth the significant risk of toxicity. the question is still open: treatment now vs treatment later? #smr2022 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4